TVB‐2640 (ASC‐40, Alcletis and 3V‐Bioscience), which shares molecular similarities with TVB‐3166, is being used in a phase I clinical trial for patients with solid tumors (NCT02223247) as well as in phase II trials for colon cancer (NCT02980029), KRAS non‐small cell lung carcinomas (NCT03808558), astrocytomas (NCT03032484), and ErbB2‐positive breast cancer (NCT03179904). Here, KRAS is linked to small cell lung carcinoma.